Brian Skorney
Stock Analyst at Baird
(3.26)
# 1,042
Out of 5,157 analysts
118
Total ratings
44.05%
Success rate
3.9%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $63 → $97 | $59.04 | +64.30% | 2 | Mar 9, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $91.75 | -4.09% | 6 | Dec 9, 2025 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $23.05 | -4.56% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $17.58 | -14.65% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $36.98 | +67.66% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $10.46 | +397.13% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $129.54 | +43.58% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $39.05 | +209.86% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $19.99 | +60.08% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $190.48 | +33.87% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $652 → $587 | $774.66 | -24.22% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $146.00 | -31.51% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $12.28 | +144.30% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $14.17 | +41.14% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $26.34 | -5.09% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $377.64 | -43.07% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $6.85 | +308.76% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $9.38 | +315.78% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $492.38 | -33.99% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $25.64 | -61.00% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.60 | +45,080.72% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.85 | +23.71% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.01 | +29,602.97% | 3 | May 7, 2018 |
Xenon Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $63 → $97
Current: $59.04
Upside: +64.30%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $91.75
Upside: -4.09%
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $23.05
Upside: -4.56%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $17.58
Upside: -14.65%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $36.98
Upside: +67.66%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $10.46
Upside: +397.13%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $129.54
Upside: +43.58%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $39.05
Upside: +209.86%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $19.99
Upside: +60.08%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $190.48
Upside: +33.87%
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $774.66
Upside: -24.22%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $146.00
Upside: -31.51%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $12.28
Upside: +144.30%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $14.17
Upside: +41.14%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $26.34
Upside: -5.09%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $377.64
Upside: -43.07%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $6.85
Upside: +308.76%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $9.38
Upside: +315.78%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $492.38
Upside: -33.99%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $25.64
Upside: -61.00%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.60
Upside: +45,080.72%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.85
Upside: +23.71%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.01
Upside: +29,602.97%